Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director · President | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,215 |
Ending reported balance
After 2026-07-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-31 · Grant · Acquired 152,353 · Balance 153,353 F1: Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023. Row 2 · 2026-07-31 · Tax withholding · Disposed 72,138 · Balance 81,215 F2: Represents shares withheld to pay tax withholding obligations due on the date of settlement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023.
F2: Represents shares withheld to pay tax withholding obligations due on the date of settlement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 21:22 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Tax withholdingCommon Stock | 72,138 | $3.38 | $243,826.44 |
DisclosureSEC source: 0001193125-26-333133 · ownership.xml · nonDerivative · entry 2 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,215 F2 · kind: Represents shares withheld to pay tax withholding obligations due on the date of settlement. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 21:22 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantCommon Stock | 152,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-333133 · ownership.xml · nonDerivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,353 F1 · kind: Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004916 · ownership.xml · derivative · entry 2 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. F3 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 243,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004916 · ownership.xml · derivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 243,000 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 243,000 shares of common stock, which option vests with respect to 60,750 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 840,438 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-130273 · ownership.xml · derivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840,438 Underlying: Common Stock · 840,438 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 840,438 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 315,164 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 525,274 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 428,148 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000950170-24-073770 · ownership.xml · derivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,148 Underlying: Common Stock · 428,148 shares Expires 2033-05-01 F1 · derivative.exercise_date: This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 428,148 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 107,037 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 321,111 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:50 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 317,147 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026733 · doc4.xml · derivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,147 Underlying: Common Stock · 317,147 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 317,147 shares of Common Stock, which option vests with respect to 79,287 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 23:11 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006364 · doc4.xml · derivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 21:05 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | PurchaseCommon Stock | 1,000 | $2.60 | $2,596.90 |
DisclosureSEC source: 0001209191-22-058608 · doc4.xml · nonDerivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: This Form 4 reports an open market purchase by the Reporting Person of shares of common stock in accordance with the Issuer's trading policies. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:37 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006486 · doc4.xml · derivative · entry 1 Perrin Steven · CIK 0001824545 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.